BibTex format
@article{Allegretti:2021:ibd/izaa283,
author = {Allegretti, JR and Kelly, CR and Grinspan, A and Mullish, BH and Hurtado, J and Carrellas, M and Marcus, J and Marchesi, JR and McDonald, JAK and Gerardin, Y and Silverstein, M and Pechlivanis, A and Barker, GF and Miguens, Blanco J and Alexander, JL and Gallagher, KI and Pettee, W and Phelps, E and Nemes, S and Sagi, SV and Bohm, M and Kassam, Z and Fischer, M},
doi = {ibd/izaa283},
journal = {Inflammatory Bowel Diseases},
pages = {1371--1378},
title = {Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent <i>C. difficile</i> Infection},
url = {http://dx.doi.org/10.1093/ibd/izaa283},
volume = {27},
year = {2021}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD) is a clinical challenge. Fecal microbiota transplantation (FMT) has emerged as a recurrent CDI therapy. Anecdotal concerns exist regarding worsening of IBD activity; however, prospective data among IBD patients are limited.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Secondary analysis from an open-label, prospective, multicenter cohort study among IBD patients with 2 or more CDI episodes was performed. Participants underwent a single FMT by colonoscopy (250 mL, healthy universal donor). Secondary IBD-related outcomes included rate of de novo IBD flares, worsening IBD, and IBD improvement—all based on Mayo or Harvey-Bradshaw index (HBI) scores. Stool samples were collected for microbiome and targeted metabolomic profiling.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Fifty patients enrolled in the study, among which 15 had Crohn’s disease (mean HBI, 5.8 ± 3.4) and 35 had ulcerative colitis (mean partial Mayo score, 4.2 ± 2.1). Overall, 49 patients received treatment. Among the Crohn’s disease cohort, 73.3% (11 of 15) had IBD improvement, and 4 (26.6%) had no disease activity change. Among the ulcerative colitis cohort, 62% (22 of 34) had IBD improvement, 29.4% (11 of 34) had no change, and 4% (1 of 34) experienced a de novo flare. Alpha diversity significantly increased post-FMT, and ulcerative colitis patients became more similar to the donor than Crohn’s disease patients (P = 0.04).</jats:p>
AU - Allegretti,JR
AU - Kelly,CR
AU - Grinspan,A
AU - Mullish,BH
AU - Hurtado,J
AU - Carrellas,M
AU - Marcus,J
AU - Marchesi,JR
AU - McDonald,JAK
AU - Gerardin,Y
AU - Silverstein,M
AU - Pechlivanis,A
AU - Barker,GF
AU - Miguens,Blanco J
AU - Alexander,JL
AU - Gallagher,KI
AU - Pettee,W
AU - Phelps,E
AU - Nemes,S
AU - Sagi,SV
AU - Bohm,M
AU - Kassam,Z
AU - Fischer,M
DO - ibd/izaa283
EP - 1378
PY - 2021///
SN - 1078-0998
SP - 1371
TI - Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent <i>C. difficile</i> Infection
T2 - Inflammatory Bowel Diseases
UR - http://dx.doi.org/10.1093/ibd/izaa283
UR - http://hdl.handle.net/10044/1/84552
VL - 27
ER -
